Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of February 2021. The report details a strategic amendment to a clinical trial collaboration with Bristol-Myers Squibb Company (BMS) regarding the development of Compugen's investigational anti-PVRIG antibody, COM701.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a contractual amendment and clinical trial progress.
Material Changes and Contractual Updates
- Amendment Execution: On February 19, 2021, Compugen entered into Amendment No. 2 to the Master Clinical Trial Collaboration Agreement with BMS.
- Study Expansion: The parties agreed to expand the Phase 1b combination study (Dual Combination) of COM701 and BMS's Opdivo (nivolumab) in patients with advanced solid tumors. Compugen will sponsor this expansion cohort, while BMS will provide Opdivo at no cost.
- Enrollment Status: Enrollment for the dual combination dose escalation study has been completed.
- Triple Combination: The collaboration continues a triple combination study evaluating COM701, Opdivo, and BMS's anti-TIGIT antibody (BMS-986207).
- Exclusivity Revision: The exclusivity period granted to BMS was revised to end on the earlier of: (i) six months after the completion of the Triple and Dual Combination studies, or (ii) December 31, 2023.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the amendment and the strategic progression of the clinical trials. The filing notes that all other terms of the original agreement remain unchanged. No specific financial guidance, risk factors, or contingencies are detailed in this specific document beyond the standard incorporation by reference into the Company's Form F-3 Registration Statement.
Key Facts for Investor Verification
- Verify the specific financial terms and potential milestone payments associated with the Phase 1b expansion cohort in the full text of Amendment No. 2 (Exhibit 10.1).
- Confirm the timeline for the completion of the Triple and Dual Combination studies to assess the exact expiration date of BMS's exclusivity.
- Review the press release (Exhibit 99.1) for any additional details on the clinical trial design or patient selection criteria.
- Check subsequent filings for updates on the safety and tolerability data resulting from the completed dose escalation study.